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Abstract
Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility in women. It is also associated with metabolic
disturbances that place women at increased risk for obesity and type 2 diabetes. There is strong evidence for familial clustering
of PCOS and a genetic predisposition. However, the gene(s) responsible for the PCOS phenotypes have not been elucidated.
This two-phase family-based and case-control genetic study was designed to address the question of whether SNPs identified
as susceptibility loci for obesity in genome-wide association studies (GWAS) are also associated with PCOS and elevated BMI.
Members of 439 families having at least one offspring with PCOS were genotyped for 15 SNPs previously shown to be
associated with obesity. Linkage and association with PCOS was assessed using the transmission/disequilibrium test (TDT).
These SNPs were also analyzed in an independent case-control study involving 395 women with PCOS and 176 healthy
women with regular menstrual cycles. Only one of these 15 SNPs (rs2815752 in NEGR1) was found to have a nominally
significant association with PCOS (x2 = 6.11, P = 0.013), but this association failed to replicate in the case-control study. While
not associated with PCOS itself, five SNPs in FTO and two in MC4R were associated with BMI as assessed with a quantitative-
TDT analysis, several of which replicated association with BMI in the case-control cohort. These findings demonstrate that
certain SNPs associated with obesity contribute to elevated BMI in PCOS, but do not appear to play a major role in PCOS per se.
These findings support the notion that PCOS phenotypes are a consequence of an oligogenic/polygenic mechanism.
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine
disorder affecting 5–8% of reproductive age women. In addition to
the primary features of hyperandrogenemia, chronic anovulation
and infertility, women with PCOS are also at increased risk for
obesity, insulin resistance and type 2 diabetes. Forty to 80% of
women with PCOS are overweight or obese [1–3]. Moreover, in
obese women the reproductive phenotype of PCOS can be
reversed by weight loss [4], implicating BMI as a major
determinant of the manifestation of the syndrome. Collectively,
these observations strongly suggest that obesity and PCOS are
linked co-morbidities. Furthermore, because of the common co-
occurrence of these features, PCOS casts a shadow well beyond
the reproductive years when it is diagnosed.
Legro et al. [5] described evidence for familial aggregation of
hyperandrogenemia in PCOS that is consistent with a genetic
contribution to disease susceptibility. However, the diagnostic
criteria used for PCOS in the Legro et al. study (hyperandrogen-
emia and oligomenorrhea/amenorrhea), and others that have
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presented strong evidence for familial clustering do not include
metabolic phenotypes such as obesity or indices of glucose
metabolism or insulin action. Few genetic studies on PCOS have
focused on obesity. Consequently the contribution of genes that
influence body composition in PCOS remains to be clarified.
Recent technological and computational advances in genome-
wide association studies (GWAS) have resulted in a series of studies
designed to identify susceptibility loci for many complex genetic
diseases, including obesity and type 2 diabetes. These large scale
genetic association studies have identified variations in or near
FTO, GNPDA2, INSIG2, KCTD15, MC4R, MTCH2, NEGR1,
SH2B1 and TMEM18 as susceptibility loci for obesity [6–10].
Given the high prevalence of obesity in women with PCOS, it is
crucial to investigate the genetic contribution the susceptibility loci
for obesity make to PCOS. A study by Barber et al. [11] identified
an association between the FTO SNP rs9939609 and PCOS, but
determined that its effect was likely through BMI. Similarly, Tan
et al. [12] and Wehr et al. [3] also demonstrated an association
between BMI and rs9939609 in women with PCOS. In this report
we examined SNPs in or near a set of nine genes associated with
obesity based on findings from GWAS or large association studies.
Materials and Methods
PCOS families
SNP markers were genotyped in 439 families with PCOS: 44
multiplex families (two or more affected daughters and parents) and
395 simplex families (one affected daughter and parents). The total
number of offspring with PCOS was 488. Body mass index (BMI)
was available for 463 of the PCOS probands and sisters. Clinical
characteristics of the probands and sisters are presented in Table 1.
The self-identified ethnicities of probands in the families were: 87%
white, 4% Hispanic, 1% black and 7% other or unknown.
Diagnostic criteria for PCOS have been described in detail
elsewhere [5,13]. Probands and sisters were considered affected if
they had 6 or fewer menses per year and elevated total testosterone
(greater than 58 ng/dl) or elevated non-SHBG-bound testosterone
(greater than 15 ng/dl); these thresholds are 2 S.D. greater than
the mean of our normal controls.
Case-control cohort
The replication cohort consisted of 395 unrelated White PCOS
patients and 176 White control women recruited at two centers,
the University of Alabama at Birmingham (248 PCOS and 152
controls) and Cedars-Sinai Medical Center (147 PCOS and 24
controls). Cases were premenopausal, non-pregnant, on no
hormonal therapy, including oral contraceptives, for at least three
months, and met 1990 NIH criteria for PCOS [14]. Parameters
for defining hirsutism, hyperandrogenemia, ovulatory dysfunction,
and exclusion of related disorders were previously reported [15].
Clinical characteristics of the case-control cohort are presented in
Table 1. Controls were healthy women, with regular menstrual
cycles and no evidence of hirsutism, acne, alopecia, or endocrine
dysfunction and had not taken hormonal therapy (including oral
contraceptives) for at least three months.
This study was approved by the institutional review boards of
the University of Pennsylvania, Pennsylvania State University
College of Medicine, Brigham and Women’s Hospital, North-
western University, the University of Alabama at Birmingham and
Cedars-Sinai Medical Center. All subjects provided written
informed consent for participation in this study.
SNP genotyping
SNPs were chosen for genotyping in the PCOS families on the
basis of published findings in GWA studies with obesity. A total of
15 SNPs associated with obesity that were genotyped are located
in or near FTO (rs1421085, rs17817449, rs8050136, rs9939609
and rs9930506) [9,10,16], GNPDA2 (rs10938397), KCTD15
(rs11084753), MTCH2 (rs10838738), NEGR1 (rs2815752), SH2B1
(rs7498665), TMEM18 (rs6548238) [9], MC4R (rs17782313 and
rs12970134) [7,9,17], and in INSIG2 (rs7566605 and rs2161829)
[6]. SNPs were genotyped using Applied Biosystems TaqMan SNP
Genotyping Assays. Allelic PCR products were analyzed using the
Applied Biosystems 7900HT Sequence Detection System and SDS
2.2 software. Genotypes were auto-called by SDS 2.2 software
with quality value set at 0.95. Two CEPH individuals were typed
on each of 16 96-well plates. No discrepancies were observed for
any of the SNPs, and all genotypes were in Hardy-Weinberg
equilibrium.
In the case-control cohort, genotyping was carried out using
iSelect Infinium technology, following the manufacturer’s protocol
(Illumina, San Diego, CA) [18,19]. Duplicate genotyping of 12
samples yielded a 100% concordance rate. The genotyping success
rate was 99.97%. All SNPs were in Hardy-Weinberg equilibrium.
SNPs were excluded if the genotyping failure rate was .10%; or if
the minor allele frequency was ,3%. Ultimately, of the 15 SNPs
Table 1. Clinical characteristics of PCOS in probands and sisters in the family study, controls from the case-control cohort, and
PCOS cases from the case-control cohort.
PCOS probands and sisters (N=488) Controls (N=176) PCOS cases (N=395)
Age (yr) 28 (24–32) 34 (26–41) 27 (22–32) b
BMI (kg/m2) 35.3 (28.7–41.1) 24.1 (21.9–28.5) 31.5 (25.1–39.7) a b
Total testosterone (nmol/l)* 2.46 (2.04–3.19) 1.39 (0.97–1.91) 2.39 (1.66–3.12) b c
Insulin (pmol/l) 152.8 (97.2–215.3) 50.9 (33.9–81.4) 100.5 (43.1–165.0) a b
Glucose (mmol/l) 4.88 (4.61–5.27) 4.72 (4.52–5.08) 4.72 (4.44–5.05) a
HOMA2-IR 2.72 (1.82–3.84) 0.98 (0.66–1.53) 1.72 (0.81–2.76) a b
HOMA2-%B 195.9 (152.8–240.9) 105.4 (79.4–135.5) 147.8 (99.8–200.6) a b
Data are median (interquartile range).
*Nominal testosterone values based on different assays for the probands and sisters and the case-control cohort as described in text.
aP,0.0001 compared to probands and sisters.
bP,0.0001 compared to controls.
cP = 0.002 compared to probands and sisters.
doi:10.1371/journal.pone.0016390.t001
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genotyped in the family cohort, 13 were genotyped in the case-
control cohort.
Statistical analysis
Error-checking of genotypes in the family material was
performed with Merlin software (version 1.1.2; http://www.sph.
umich.edu/csg/abecasis/merlin/index.html [20]) and families
with one or more Mendelian discrepancies for a marker were
excluded in the analysis of that markerLinkage and association
between SNPs and PCOS was tested with the TDT [21]. Odds
ratio (OR) and standard error (SE) was calculated using the
method described in Kazeem and Farrall [22]. The quantitative
TDT (QTDT) program (version 2.6.0) in Merlin was used to test
for association between the SNPs and BMI, using the orthogonal
association model and the environmental, polygenic, and additive
variance components (http://www.sph.umich.edu/csg/abecasis/
QTDT/) [20]). We corrected for multiple testing using Bonferroni
adjustment based on testing of 15 SNPs associated with obesity;
the adjusted p-value of 0.0033 corresponded to a nominal
P = 0.05.
In the case-control cohort, genotypic association with PCOS
status was evaluated using logistic regression, adjusting for
recruitment site, BMI and age. In women with PCOS, association
between genotype and BMI was performed using linear regression
adjusting for site and age. Additive, dominant, and recessive
models were examined. A P,0.05 was considered significant when
there was evidence of association in the family cohort. For other
SNPs, Bonferroni-corrected P value of 0.0038, corresponding to a
nominal P of 0.05 was utilized.
Genetic Power Calculator software (http://pngu.mgh.harvard.
edu/,purcell/gpc/[23]) was used to determine that with the
sample size of each independent cohort, there was approximately
80% power (P= 0.05) to detect a relative risk ration of 3.0.
Results
To determine if sequence variants in genes associated with
obesity contribute to genetic susceptibility to PCOS, we used the
TDT to analyze 15 SNPs in nine genes for association with PCOS
in our collection of 439 families (Table 2). The TDT analysis was
nominally significant for only one SNP: rs2815752 in NEGR1
(x2 = 6.11, P= 0.013), which was not significant after adjustment
for multiple testing, nor was it significant in an independent case-
control analysis (Table 2).
Since all 15 SNPs have been associated with obesity in the
general population, we carried out TDT analysis separately in
obese (BMI.30 kg/m2) and non-obese (BMI,29.9 kg/m2) off-
spring to determine whether any of them were associated with
PCOS in each BMI stratum. ne SNP in FTO, two in MC4R and
one in NEGR1 were over-transmitted to the obese offspring (FTO
rs1421085: x2 = 4.99, P= 0.026; MC4R rs17782313 and
rs12970134: x2 = 8.24, P= 0.004 and x2 = 5.065, P = 0.024,
respectively; NEGR1 rs2815752: x2 = 6.26, P= 0.012). However,
none were significant after correction for multiple testing.
QTDT analysis further revealed that five SNPs in FTO and two
in MC4R were significantly associated with obesity in the PCOS
families (Table 2). Of these, three SNPs in FTO remained
significant after correction for multiple testing: rs1421085
(Pcorrected = 0.011), rs17817449 (0.021), and rs9930506 (0.041).
We next investigated association between 13 of these 15 SNPs
and BMI in an independent case-control study. None of these
SNPs was associated with PCOS (Table 3). No SNPs were
associated with PCOS in analyses stratified by obesity.
In additive and recessive models, four of the five FTO SNPs
were associated with BMI in women with PCOS (Table 4). One of
the two MC4R SNPs was associated with BMI in the recessive
model (Table 4). None of these FTO or MC4R SNPs was
associated with BMI in the control group.
It should be noted that the affected women in the family cohort
were heavier, more hyperandrogenemic based on nominal
testosterone values, and had more prominent metabolic abnor-
malities than the PCOS women from the case-control cohort,
which may be due to the fact that the former were all
hyperandrogenemic by definition and, therefore, had a more
profound PCOS phenotype (Table 1).
Discussion
In this study, we examined whether DNA variants that
contribute to obesity also influence susceptibility to PCOS. This
study was designed to address the question of whether the frequent
co-occurrence of obesity with PCOS might be due to underlying
genetic mechanisms that are common to these conditions or
whether they are separate and independent. The initial phase of
this study was a family based analysis followed by confirmation of
the findings in an independent case-control cohort. Ideally,
women with PCOS in both cohorts would have been diagnosed
using the same criteria. This was not the case because these are
both pre-existing cohorts. Despite this difference several FTO
SNPs were associated with BMI in both studies.
Among the 15 obesity-associated SNPs that were assessed by
family-based TDT analysis for association with PCOS, rs2815752
near NEGR1 was nominally significant (P = 0.013). Several SNPs
in FTO which are not significantly associated with PCOS, were
associated with obesity in affected women in both the family and
case-control cohorts. Other studies have also found a similar
association between DNA variation in FTO and PCOS. Barber et
al [11] reported an association between the FTO SNP rs9939609
and PCOS, which became less significant after adjustment for
BMI. In studies by Tan et al. [12] and Wehr et al. [3], association
between SNPs in FTO and PCOS phenotype was not considered,
but both reported an association of the rs9939609-allele A with
increased BMI. These results suggest that variation in FTO is
associated with obesity in PCOS, consistent with our findings, but
that the contribution FTO makes to the PCOS reproductive
phenotype is uncertain.
Our goal in this study was to determine whether specific SNPs
associated with obesity in GWAS contributed to PCOS. Given the
limited power in this study to detect SNPs with only a small effect
(OR,3), we cannot rule out that these, or other SNPs in the same
genes, may be found to be associated with PCOS in studies of
larger cohorts. It is noteworthy that in a study of the contribution
SNPs associated with type 2 diabetes make to PCOS, Biyasheva et
al. [24] reported that while the two SNPs identified in GWAS
were not significant in PCOS, two other SNPs mapping
approximately 100 kb centrometic to them were significantly
associated with PCOS.
Numerous candidate gene studies designed to identify PCOS
susceptibility loci have been published, but most nominally
significant positive findings have not been confirmed in follow-
up replication studies (reviewed in [25,26]). The most well
established candidate region remains D19S884, a microsatellite
marker in intron 55 of FBN3, located on 19p13.2 about 800 kb
centrometic to the insulin receptor gene [13,27]. However, there is
no evidence to date that the D19S884 allele associated with PCOS
influences insulin receptor gene expression, although it has been
associated with insulin resistance [28]. Of relevance to the present
Obesity Genes and PCOS
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study that revealed an association of MC4R SNPs with BMI, we
recently found an association for SNPs in the gene that encodes
the MC4R ligand, POMC, with PCOS [29]. Interestingly, humans
with mutations in POMC and MC4R and mice with targeted
deletions in these genes have an obesity phenotype [30,31]. Thus,
a neuroendocrine pathway may connect the reproductive and
metabolic phenotypes found in women with PCOS.
Several but not all SNP associations observed in the family
cohort were replicated in the case-control cohort. The relatively
small number of subjects in the control group may have affected
Table 2. Obesity susceptibility loci identified in GWAS tested by TDT and QTDT 439 PCOS families (N = 488 probands and sisters)
for linkage and association with PCOS and BMI.
TDT association with PCOS
QTDT association
with BMI
Gene SNP Allelesa MAFb
Over-
transmitted
Allele Tc not Tc
Total
Tc
Transmission
Frequency
TDT
x 2 P-valued OR SE QTDTx 2 P-valuee
FTO rs1421085 T/C 0.45 C 232 195 427 0.543 3.21 0.073 1.178 0.096 11.42 0.0007
rs17817449 T/G 0.453 G 235 214 449 0.523 0.98 0.322 1.081 0.093 10.25 0.0014
rs8050136 C/A 0.451 A 247 227 474 0.521 0.84 0.358 1.081 0.091 7.22 0.0072
rs9939609 T/A 0.456 A 235 223 458 0.513 0.31 0.575 1.043 0.092 5.30 0.0213
rs9930506 A/G 0.467 G 229 213 442 0.518 0.58 0.447 1.068 0.094 8.98 0.0027
GNPDA2 rs10938397 A/G 0.427 G 201 200 401 0.501 0.002 0.964 1.025 0.099 0.67 0.4131
INSIG2 rs7566605 G/C 0.314 G 108 104 212 0.509 0.06 0.784 1.048 0.136 0.23 0.6315
rs2161829 G/A 0.417 A 126 120 246 0.512 0.15 0.702 1.041 0.127 0.42 0.5169
KCTD15 rs11084753 G/A 0.336 G 204 196 400 0.510 0.16 0.689 1.055 0.099 1.37 0.2418
MC4R rs17782313 T/C 0.257 C 167 142 309 0.540 2.02 0.155 1.207 0.112 6.56 0.0104
rs12970134 G/A 0.28 A 164 148 312 0.526 0.82 0.365 1.132 0.111 7.81 0.0052
MTCH2 rs10838738 A/G 0.361 G 209 195 404 0.517 0.49 0.486 1.076 0.099 0.38 0.5376
NEGR1 rs2815752 A/G 0.352 A 221 172 393 0.562 6.11 0.013 1.285 0.100 0.81 0.3681
SH2B1 rs7498665 A/G 0.381 G 194 189 383 0.507 0.07 0.799 1.010 0.101 1.76 0.1846
TMEM18 rs6548238 C/T 0.172 C 139 130 269 0.517 0.30 0.583 1.092 0.121 0.23 0.6315
aSNP alleles, minor allele appears second.
bMAF, minor allele frequency for SNP.
cT, number of transmissions to affected offspring in the TDT analysis.
dP values are uncorrected.
doi:10.1371/journal.pone.0016390.t002
Table 3. Obesity susceptibility loci identified in GWAS tested by logistic regression for association with PCOS in the case-control
cohort (395 cases, 176 controls).
ADDITIVE DOMINANT RECESSIVE
Gene SNP
Minor
allele N OR STAT P N OR STAT P N OR STAT P
FTO rs1421085 C 571 0.830 21.080 0.280 571 0.633 21.819 0.069 571 1.134 0.385 0.700
rs17817449 G 571 0.834 21.040 0.298 571 0.646 21.725 0.084 571 1.116 0.337 0.736
rs8050136 A 571 0.842 20.985 0.325 571 0.657 21.670 0.095 571 1.134 0.382 0.702
rs9939609 A 571 0.820 21.137 0.256 571 0.635 21.799 0.072 571 1.088 0.258 0.796
rs9930506 G 571 0.844 20.972 0.331 571 0.642 21.686 0.092 571 1.103 0.318 0.751
GNPDA2 rs10938397 G 571 1.141 0.775 0.439 571 1.020 0.082 0.935 571 1.536 1.316 0.188
KCTD15 rs11084753 A 570 1.345 1.662 0.096 570 1.607 2.053 0.040 570 1.088 0.220 0.826
MC4R rs17782313 C 571 1.341 1.459 0.145 571 1.450 1.564 0.118 571 1.259 0.410 0.682
rs12970134 A 571 1.377 1.645 0.100 571 1.619 2.041 0.041 571 0.979 20.044 0.965
MTCH2 rs10838738 G 571 1.062 0.359 0.720 571 1.044 0.189 0.851 571 1.171 0.454 0.650
NEGR1 rs2815752 G 571 0.953 20.294 0.769 571 0.962 20.167 0.867 571 0.898 20.342 0.732
SH2B1 rs7498665 G 571 0.947 20.326 0.744 571 1.011 0.046 0.963 571 0.788 20.717 0.474
TMEM18 rs6548238 T 571 0.817 20.949 0.343 571 0.728 21.304 0.192 571 1.599 0.634 0.526
doi:10.1371/journal.pone.0016390.t003
Obesity Genes and PCOS
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our ability to achieve replication. Thus, to more firmly rule out the
non-replicated associations herein, replication efforts in much
larger cohorts would be needed.
Given that PCOS is associated with obesity in a significant
number of women, it is necessary to consider the interaction of
genes underlying this complex phenotype. At one extreme would
be non-overlapping sets of genes that predispose to PCOS and
obesity. At the other extreme, one set of genes might contribute to
both conditions (i.e. the underlying genetic predisposition is the
same) with different environmental factors or modifiers triggering
disease progression down one path or another. The third
possibility is a combination of these two scenarios, with genes in
pathways predisposing for obesity interacting or converging to
enhance the risk of PCOS. The interaction between MC4R and
POMC variants represents an example of this mechanism.
In conclusion, SNPs in FTO and MC4R were found to be
associated with BMI in PCOS women, but appear not to
contribute in a major way to the reproductive phenotypes of
PCOS. However, these variants may interact with other genes
(e.g., POMC) to predispose women to PCOS, consistent with the
notion that PCOS is an oligogenic/polygenic disorder.
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